Debanjan Ray Sells 2,500 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $20.58, for a total transaction of $51,450.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Debanjan Ray also recently made the following trade(s):
- On Wednesday, November 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $50,000.00.
- On Monday, October 2nd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The stock was sold at an average price of $18.10, for a total transaction of $45,250.00.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down $0.24 on Tuesday, hitting $20.55. 389,015 shares of the company’s stock were exchanged, compared to its average volume of 278,100. CytomX Therapeutics, Inc. has a 1-year low of $10.40 and a 1-year high of $24.67.
Several research firms recently issued reports on CTMX. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective for the company. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. Finally, Oppenheimer restated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $31.88.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.